Genetic Change Clinical Trial
Official title:
Study on Gene Evolution and Anti-VEGF Treatment Response of Different Subtypes of Glioma Based on ctDNA
Little is known about the evolution of genetic and epigenetic changes that occur in the progression of glioma. We inferred the evolution trajectories of matched pairs of primary tumors and progression tumor in situ fluid (TISF) based on deep whole-genome-sequencing data (ctDNA). A monocentric, Gene grouping controlled trial design was used to select patients. and to compare gene evolution of different subtypes of glioma under therapy. To predict the molecular reaction of bevacizumab treatment, clarify the mechanism of drug resistance of bevacizumab treatment.
Status | Not yet recruiting |
Enrollment | 100 |
Est. completion date | December 31, 2026 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Age 18 to 75 years, both male and female (including 18 and 75 years old) glioma; - Willing to accept treatment and sign informed consent. Exclusion Criteria: - Participants with other infection disease or immunodeficiency disease; - other central infectious diseases; - malignant tumor of non-nervous system; - drug abuse; - severe psychiatric disease; - uncontrolled diabetes; |
Country | Name | City | State |
---|---|---|---|
China | Henan Provincial People's Hospital | Zhengzhou | Henan |
Lead Sponsor | Collaborator |
---|---|
Henan Provincial People's Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Different subtypes of glioma have different therapeutic responses to bevacizumab | We evaluated the efficacy of bevacizumab on different subtypes of glioma at recurrence according to delta-VAF and Ratio combined with imaging.The mean change in VAF (delta-VAF) was calculated per patient as the sum of the ontreatmentVAF minus the pretreatment VAF for each detected SNV or indel divided by the number of detected SNVs or indels, we found that the "molecular responce" model could generally be represented in simpler terms through a ratio of ontreatment VAF to pretreatment VAF | 96 weeks | |
Primary | the molecular mechanism of bevacizumab resistance in vivo. | We compared and analyzed the genes before and after bevacizumab treatment according to the gene evolution of ctDNA.To clarify the molecular mechanism of bevacizumab resistance. | 144 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03644355 -
Asthma and Obesity Diet Versus Exercise
|
N/A | |
Recruiting |
NCT06182722 -
Association of Peripheral Immune Cells With Antidepressant Treatment Response
|
||
Recruiting |
NCT04481061 -
Engaging Adolescents in Decisions About Return of Genomic Research Results
|
N/A | |
Recruiting |
NCT04110769 -
Development of Biomarker for the Evaluation of Response After Neoadjuvant Therapy in Patients With Pancreatic Cancer
|
N/A | |
Recruiting |
NCT05398380 -
Liver Transplantation for Non-resectable Colorectal Liver Metastases: Translational Research
|
N/A | |
Recruiting |
NCT04216537 -
Survival Significance of Molecular Pathology and Genetic Variation in Brain Gliomas
|
||
Not yet recruiting |
NCT05712980 -
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation
|
||
Recruiting |
NCT05375331 -
Clinical and Genetic Markers of Bone Metabolism in Children Under One Year
|
||
Completed |
NCT04952662 -
Candidate Gene Association Study With Injury in Elite Male Youth Football Players
|
||
Completed |
NCT03672786 -
Gene Expression in Intervened Athletes
|
N/A |